文献速递脊柱脊髓外科神经肿瘤

骨形态发生蛋白-2在脊柱肿瘤手术中的应用:一项全国性调查

Use of Bone Morphogenetic Protein-2 in Vertebral Column Tumor Surgery: A National Investigation.
PubMed 文献 · World Neurosurg · 2018-05-04

基于美国全国住院患者样本数据库(2012-2014年),共识别9375例因脊柱肿瘤行融合手术的患者,其中540例(5.8%)使用了骨形态发生蛋白-2(BMP-2)。BMP-2使用率在原发性良性肿瘤、原发性恶性肿瘤和转移性病变中分别为4.9%、7.6%和5.7%(P=0.607)。使用BMP-2的患者较少合并脊髓硬膜外压迫(37.0% vs 49.2%;P=0.014),更可能接受择期手术(53.7% vs 37.7%;P<0.001),且南部地区使用率最高(7.4%;P=0.002)。

要点

  • 脊柱肿瘤融合手术中BMP-2总体使用率为5.8%(540/9375例)。
  • BMP-2使用与无脊髓硬膜外压迫和择期手术相关,南部地区使用率最高。
  • BMP-2组与非BMP-2组总体并发症率无显著差异(11.1% vs 13.4%;P=0.504)。

核心结论

  • BMP-2已被超说明书用于促进脊柱融合,但在脊柱肿瘤患者中的使用存在争议;本全国性研究中,BMP-2使用率在南部地区、无脊髓硬膜外压迫的患者和择期病例中最高。

研究设计与样本

  • 查询美国全国住院患者样本数据库(2012-2014年),识别因脊柱肿瘤(原发性良性、原发性恶性或转移性)行脊柱融合手术的患者,计算BMP-2使用率并分析相关患者和手术因素。

主要发现

  • 共识别9375例患者,其中540例使用BMP-2(5.8%)。
  • BMP-2使用率在原发性良性肿瘤手术中为4.9%,原发性恶性肿瘤为7.6%,转移性病变为5.7%(P=0.607)。
  • 总体并发症率为13.2%,非BMP-2组为13.4%,BMP-2组为11.1%(P=0.504)。
  • BMP-2组较少出现就诊时脊髓硬膜外压迫(37.0% vs 49.2%;P=0.014),更可能接受择期手术(53.7% vs 37.7%;P<0.001)。
  • 南部地区BMP-2使用率最高(7.4%;P=0.002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the rate of bone morphogenetic protein-2 (BMP-2) use in vertebral column tumor surgery. METHODS: The Nationwide Inpatient Sample database (2012-2014) was queried to identify patients who underwent spinal fusion for vertebral column tumors (primary benign, primary malignant, or metastatic). The rate of BMP-2 use was calculated, and patient and operative factors associated with its use were also investigated. RESULTS: We identified 9375 patients who underwent fusion surgery for spinal tumors between 2012 and 2014, with 540 cases using BMP-2 (5.8%). Preoperative diagnosis revealed that the rate of BMP-2 use in primary benign tumor surgery was 4.9%, 7.6% for primary malignant tumors, and 5.7% for metastatic lesions (P = 0.607). The overall complication rate was 13.2% (13.4% in the NO-BMP-2 group vs. 11.1% in the BMP-2 group; P = 0.504). Patients who received this growth factor were less likely to have epidural spinal cord compression at presentation (37.0% vs. 49.2%; P = 0.014), and more likely to have elective surgery (53.7% vs. 37.7%; P < 0.001). Analysis of hospital location indicated that the highest use of BMP-2 was in the South (7.4% rate; P = 0.002). There was no statistical difference between age, sex, insurance status, comorbidities, the presence of a pathologic fracture, or the use of inpatient radiotherapy or chemotherapy between patients who received BMP-2 and controls. CONCLUSIONS: BMP-2 has been used off-label to promote arthrodesis; however, its use in patients with spinal tumors is controversial. In this national study, BMP-2 use was highest in the South, in patients without epidural cord compression at presentation, and in elective cases.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. De la Garza Ramos R, Nakhla J, Echt M, et al. Use of Bone Morphogenetic Protein-2 in Vertebral Column Tumor Surgery: A National Investigation. World Neurosurg. 2018. PMID: 29733987. doi:10.1016/j.wneu.2018.04.190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。